BioBalance Corp. (BioBalance), a wholly owned subsidiary of New York Health Care, Inc.(OTC BB: BBAL), announced today that it has been awarded U.S. Patent 7,018,629 for the use of Probactrix®, its patented strain of the biotherapeutic agent E.coli M-17, in the treatment of Inflammatory Bowel Disease (IBD). BioBalance applied for the patent on January 22, 2003 and it was awarded on March 28, 2006.
